The U.S. Department of Health and Human Services (HHS) and the National Institutes of Health (NIH) have announced a major advance in vaccine science with the launch of “Generation Gold Standard,” a government-led initiative to develop a universal vaccine platform aimed at protecting against a wide range of pandemic-prone viruses. Utilizing a beta-propiolactone (BPL)-inactivated, whole-virus approach, the initiative seeks to redefine America’s preparedness and response strategy to viral threats.
Continues after this brief message…
Did you know? Paid supporters get a reduced ad experience!
Thank you for supporting Radio Free Hub City!
The platform, developed by NIH’s National Institute of Allergy and Infectious Diseases (NIAID), is centered around broad-spectrum vaccine candidates BPL-1357 and BPL-24910. These vaccines are designed to offer cross-protection against multiple strains of influenza, including H5N1 avian flu, as well as coronaviruses such as SARS-CoV-2, SARS-CoV-1, and MERS-CoV. Unlike traditional vaccines that target specific viral strains, the BPL method preserves the full structure of the virus while eliminating its infectivity, stimulating both B and T cell responses for more durable immunity.
Article continues after these messages…
While other outlets focus on getting quotes from politicians who don't even live in our congressional district, we're focused on providing the hard-hitting truths and facts without political spin. We don't lock our news behind a paywall, will you help us keep it that way? If you're tired of news sweetened with confirmation bias, consider becoming a monthly supporter. But if you're not, that's fine too—we're confident in our mission and will be here if you decide you're ready for the truth. Just $5/month helps fund our local reporting, live election night coverage, and more.
Become a paid supporter for reduced ad experience!
Currently, the intranasal version of BPL-1357 is undergoing Phase Ib and Phase II/III clinical trials. It aims to prevent not just infection but also transmission—an area where existing COVID-19 and flu vaccines have shown limited efficacy. The Generation Gold Standard program also serves as a realignment of the Biomedical Advanced Research and Development Authority (BARDA) to its original mandate under the Public Health Service Act, expanding its focus beyond presently circulating viral threats.
Looking ahead, NIH plans to initiate clinical trials for universal influenza vaccines in 2026, with a goal of obtaining FDA approval by 2029. The intranasal flu vaccine is also on course for FDA review within the same timeline. The adaptable BPL platform may also be deployed in the future to combat respiratory syncytial virus (RSV), metapneumovirus, and parainfluenza, with the added benefit of preventing antigenic drift in avian influenza strains.
Article by multiple RFHC contributors, based upon information from a press release issued by the U.S. Department of Health and Human Services and the National Institutes of Health
Do you believe we got something wrong? Please read our publishing standards and corrections policy.
Did you know? Supporters get a reduced ad experience!
Sponsored Articles
Get daily and breaking news for Washington County, MD area from Radio Free Hub City. Sign up with your email today!
Paid supporters have a reduced ad experience!
Discover more from Radio Free Hub City
Subscribe to get the latest posts sent to your email.



